LianBio (NASDAQ:LIAN) Shares Down 2.1% – Here’s What Happened

Shares of LianBio (NASDAQ:LIAN) traded down 2.1% on Friday . The stock traded as low as $0.20 and last traded at $0.20. 14,001 shares traded hands during trading, a decline of 99% from the average session volume of 1,037,083 shares. The stock had previously closed at $0.20.

LianBio Stock Performance

The firm has a 50-day moving average of $0.21 and a 200-day moving average of $0.27. The firm has a market capitalization of $21.15 million, a P/E ratio of -0.24 and a beta of 0.23.

LianBio Company Profile

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.